SMITHKLINE AUGMENTIN SALES JUMP 73% IN U.S. DURING STRONG FIRST QUARTER FLU SEASON; BRISTOL PRAVACHOL SALES UP 48% TO $374 MIL., TAXOL GROWS BY 10%

Executive Summary

SmithKline Beecham's antibiotic Augmentin soared to a 73% sales increase in the U.S. during the first quarter as a strong flu season helped produce dramatic increases in sales for anti-infective products across the industry. Augmentin posted $204 mil. in sales for the quarter in the U.S. and was SB's number one product for the period. Worldwide sales reached $419 mil., a 29% increase. SB calculates its sales figures at actual average rates of exchange and uses comparable exchange rates to calculate increases.